DeepMed Research

The Christie NHS Foundation Trust

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Established: 2007-01-01

Employees: -

Market Cap: -

Website: http://www.christie.nhs.uk/

Clinical Trials

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Cetuximab
Drug: Irinotecan
Drug: Oxaliplatin
Drug: UFT

First Posted Date: 2010-10-21

Last Posted Date: 2014-06-11

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 47

Registration Number: NCT01225744

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧
North Wales Cancer Treatment Centre, Llansantffraid Glan Conwy, United Kingdom
🇬🇧
The Royal Marsden, London and Surrey, United Kingdom

Window Study of ZD4054 in Metastatic Prostate Cancer

Not Applicable

Conditions: Prostate Cancer
Metastasis

First Posted Date: 2010-07-23

Last Posted Date: 2010-07-23

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 30

Registration Number: NCT01168141

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial

Phase 1

Terminated

Conditions: Rectal Cancer

Interventions: Drug: AZD6244
Drug: Cediranib (AZD2171)

First Posted Date: 2010-07-13

Last Posted Date: 2023-04-24

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 31

Registration Number: NCT01160926

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

MEK Inhibitor and Thoracic Radiotherapy Trial

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: AZD6244

First Posted Date: 2010-06-22

Last Posted Date: 2023-02-15

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 21

Registration Number: NCT01146756

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukaemia

Interventions: Drug: Lenalidomide

First Posted Date: 2010-05-21

Last Posted Date: 2011-12-05

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 1

Registration Number: NCT01127542

Locations: 🇬🇧
The Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧
St James's University Hospital, Leeds, United Kingdom
🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom

and more 6 locations

Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX

Conditions: Sarcoma

First Posted Date: 2009-05-12

Last Posted Date: 2013-08-26

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 400

Registration Number: NCT00900211

Locations: 🇬🇧
Middlesex Hospital, London, England, United Kingdom
🇬🇧
Royal Orthopedic Hospital NHS Trust, Birmingham, England, United Kingdom
🇬🇧
Royal National Orthopaedic Hospital NHS Trust, Cheltenham, England, United Kingdom

and more 9 locations

Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer

Not Applicable

Conditions: Breast Cancer
Cervical Cancer
Endometrial Cancer
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer
Prostate Cancer
Sarcoma
Vaginal Cancer
Vulvar Cancer

First Posted Date: 2008-01-28

Last Posted Date: 2013-08-26

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 2200

Registration Number: NCT00601406

Locations: 🇬🇧
Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom
🇬🇧
Southport and Formby District General Hospital, Southport, England, United Kingdom
🇬🇧
Christie Hospital, Manchester, England, United Kingdom

and more 8 locations

Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Cancer

First Posted Date: 2008-01-24

Last Posted Date: 2013-06-26

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 44

Registration Number: NCT00599833

Locations: 🇬🇧
Christie Hospital, Manchester, England, United Kingdom
🇬🇧
Cookridge Hospital, Leeds, England, United Kingdom

Effect of Pegvisomant on GH/IGF-I Relationship in GHD

Not Applicable

Terminated

Conditions: Severe Adult Growth Hormone Deficiency

First Posted Date: 2007-05-03

Last Posted Date: 2007-05-03

Lead Sponsor: The Christie NHS Foundation Trust

Registration Number: NCT00468624

Locations: 🇬🇧
Christie Hospital NHS Trust, Manchester, United Kingdom

Concurrent Once Daily Versus Twice Daily Radiotherapy for Limited Stage Small Cell Lung Cancer

Not Applicable

Completed

Conditions: Lung Cancer

Interventions: Radiation: Once daily radiotherapy
Radiation: Twice daily radiotherapy

First Posted Date: 2007-02-12

Last Posted Date: 2022-09-08

Lead Sponsor: The Christie NHS Foundation Trust

Target Recruit Count: 547

Registration Number: NCT00433563

Locations: 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy